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Abstract: The patient, a 16-year-old girl, was admitted to our hospital with complaints of 
right hip pain and claudication. Her past medical history indicated that 2 years earlier she 
had undergone enucleation of her left eye for a primary choroidal melanoma. Imaging studies 
revealed a osteolytic destruction with soft tissue mass involving the right hemipelvis (zone I–II). 
Single-photon emission computed tomography (SPECT) and positron emission tomography–
computed tomography (PET–CT) showed no other sites of metastases. Consequently, the patient 
underwent hemipelvic prosthesis reconstruction after tumor resection. Postoperative pathological 
diagnosis was metastatic malignant melanoma. Thirty months after treatment, imaging studies 
indicated no evidence of recurrence, and functional recovery was excellent. To our knowledge, 
the literature does not reveal any previously reported cases of ocular choroidal melanoma that 
metastasized to pelvis, meanwhile was carried out hemipelvic prosthesis reconstruction after 
pelvic tumor resection.
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Introduction
Malignant melanoma is a highly malignant tumor that mostly occurs in the skin and 
mucosa.1 It is known for its ability to metastasize to the lymph nodes, liver, lung, and 
other organs, but it rarely involves bone.2,3 Definite diagnosis of metastatic mela-
noma depends on pathological examination. The management and treatment strate-
gies for metastatic melanoma depend largely on the extent and stage of metastatic 
disease. Surgical excision, chemotherapy, and radiotherapy are the main options for 
its treatment.4 Malignant melanoma has a poor prognosis: advanced melanoma with 
distant metastases has a 5-year survival rate of 5%–14%.5
Here we present a case of pelvis metastasis from primary choroidal melanoma, 
whose clinical features and treatment with hemipelvic prosthesis reconstruction after 
tumor resection are discussed.
Case report
The general information
A 16-year-old girl presented to our department with complaints of right hip pain and 
claudication. A osteolytic destruction with soft-tissue mass involving the right hemipel-
vis (zone I–II, defined by Enneking and Dunham6) was revealed by a pelvic plain 
radiograph. A pelvic three-dimensional computed tomography (3D-CT) imaging scan 
showed tumor involvement of the ilium and acetabulum, with an extensive soft-tissue 
mass 9×8×5 cm in size (Figure 1). A pelvic MRI scan showed low T1 signal intensity OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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lesion associated with destructive changes in the right ilium 
and acetabulum. Single-photon emission computed tomogra-
phy (SPECT) and positron emission tomography–computed 
tomography (PET–CT) showed no evidence of other bony 
erosion or distant metastases. The patient’s previous medical 
history indicated that in December 2009 she had undergone 
enucleation of the left eye for a primary choroidal melanoma. 
She was lost to follow-up and not seen again until approxi-
mately 2 years later.
A diagnosis of metastatic malignant melanoma was 
confirmed on the basis of the previous medical history 
and preoperative biopsy examination of the pelvic lesion 
(Figure 2). Treating a metastatic malignant pelvic tumor 
remains a major challenge because of the complex anatomy 
of the pelvis and high rate of associated complications. After 
taking into consideration the patient’s general condition, 
young age, and possible surgical risks, the patient’s treat-
ment team decided to perform an en bloc resection and a 
limb-salvage procedure that included hemipelvic prosthesis 
reconstruction and treatment management as described by 
Harrington.7
Surgical technique
A standard iliofemoral approach was used, according to the 
classification of pelvic resections by Enneking and Dunham.6 
To reduce blood loss, lower abdominal aorta balloon occlu-
sion was employed at the beginning of operation.8,9 An 8F 
introducer sheath was used to place the aorta balloon below 
both renal arteries, so as to block the blood from the right 
superficial femoral artery. C-arm fluoroscopy was used to 
ensure proper placement. Type I–II right pelvis (ilium, peri-
acetabular, and pubis) resection and total hip arthroplasty 
were performed to achieve a clear margin. During the 1-hour 
tumor resection surgery, the balloon was loosened and the 
surgical area was taken to be in adequate hemostasis. In the 
second surgical procedure, a modular hemipelvic replace-
ment system from ChunLi Co (Beijing, People’s Republic 
of China) was placed to reconstruct the right hemipelvis. 
Finally, the muscles and soft tissues of proximal femur were 
sutured into the femoral prosthesis stem to complete the 
in-situ restoration and functional reconstruction. As a result 
of the aorta balloons, the blood loss was less than 1,000 mL 
for the entire surgery. 
The patient recovered well and was discharged after 
12 days with no occurrence of postoperative complications. 
One month postsurgery, she commenced biotherapy treatment 
to prevent tumor recurrence. Interferon alpha-2b 1,500 wiu/m2 
was injected 1–5 days per week for 4 weeks; thereafter, 
900 wiu/m2 was injected three times a week for 11 months.
Figure 1 Images from before and after surgery for pelvic metastasis.
Notes: Osteolytic destruction with soft tissue mass involving the right hemipelvis 
(zone I–II) was revealed by a pelvis plain radiograph and pelvis 3D-CT imaging scan. 
Postoperation, the prosthetic positioning was good, with no loosening and migration 
observed in the latest follow-up. The Harris hip score was 85.
Abbreviation: 3D-CT, three-dimensional computed tomography.
Figure 2 Preoperative biopsy of pelvic lesion.
Notes: The melanoma had a diffuse growth pattern. The cells of the tumor consisted of 
spindle-shaped and epithelioid cells with melanin granules scattering around the nucleus 
in the cytoplasm (hematoxylin and eosin, ×200, ×400). Immunohistochemicalstains 
showed positivity for HMB45, Melan-1 antibodies (x200).
Abbreviation: HMB45, human melanoma black 45.OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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The follow up
Patient follow-up occurred at 1 month, 2 months, 3 months, 
6 months, 9 months, 12 months, and every 6 months 
thereafter. Imaging studies were focused on tumor recur-
rence and the prosthetic situation. A visual analogue scale 
(VAS) was used to evaluate the degree of pain before and 
after the treatment. Functional outcome was determined 
using the Harris hip score, the Revised Musculoskeletal 
Tumor Society Rating Scale (MSTS93) system,10 and the 
Toronto Extremity Salvage Score (TESS).11 Meanwhile, the 
Medical Outcomes Study 36-Item Short-Form Health Survey 
(SF-36)12 questionnaire was used to evaluate the quality of 
life (show as Table 1). The patient’s right-hip pain completely 
resolved following surgery. By 6 months postsurgery, she 
was quite capable of self-care, working, and going to school. 
Her Harris hip score, MSTS93 system score, and TESS score 
were excellent at the last follow up (show in Table 1). More 
than thirty months postsurgery, there is no sign of tumor 
recurrence and the prosthetic positioning is good, with no 
loosening or migration (Figure 1).
Discussion
Malignant melanoma accounts for 1%–3% of all malignancies.2,3 
It occurs more frequently in young adults, with no difference 
by gender.3 Like other malignancies, the tumor is well known 
for local recurrence as well as distant metastasis. Spread occurs 
via lymphatics as well as the blood stream to other systemic 
metastasis. Reports show that advanced-stage malignant 
metastatic melanoma (American Joint Committee on Cancer 
stage IV) bears a grave prognosis, with the median survival 
rate of 6–9 months and 5-year survival of only 5%–14%, in 
part due to a lack of effective therapy.5
For metastatic malignant melanoma, multidisciplinary 
approaches such as surgery, radiotherapy, adjuvant che-
motherapy, and biotherapy have been administered, as 
have other conservative treatments.4 In previous studies, 
there appeared to be broad consensus that a single or local 
metastatic malignant melanoma lesion should be treated 
primarily with surgical excision.4,13–16 However, pelvic 
metastatic tumors remain a major surgical challenge in 
limb-salvage surgery because of the high rate of associated 
complications, including bleeding, infection, nerve dam-
age, periprosthetic fractures, and prosthesis loosening and 
migration.13–16 In reported series, operations for hemipelvic 
resection and pelvic reconstruction took 5–10 hours, with 
blood loss on average of 7,000 mL and as high as 15,000 mL 
sometimes.14,17 As is known, the bleeding mainly occurs 
during pelvic tumor resection. The use of the lower abdomi-
nal aorta balloon occlusion technique in our case reduced 
blood loss effectively (less than 1,000 mL), which shortened 
the operation time to only 4 hours and also increased the 
opportunity for a “no touch” tumor resection, because the 
operation field was clear and clean.
It was important that muscles and soft tissues of the proxi-
mal femur are repaired and reconstructed in situ after tumor 
resection and hemipelvic prosthesis reconstruction, and that 
scientifically functional exercises were undertaken postop-
eratively to achieve encouraging outcomes. In addition, the 
patient’s pain completely resolved following surgery (VAS 
score reduction from 8 to 1), which speeded up the period 
of recovery and improved quality of life. SF-36, Harris hip, 
MSTS93, and TESS scores were used to evaluate the recovery 
effects. Quality of life was first investigated by SF-36 ques-
tionnaire with our patient. Compared with the preoperative 
scores, follow-up scores improved and returned to nearly 
normal levels by the time of the last follow-up (Table 1). 
Functional results compared favorably with other studies, 
although the SF-36 was not used in those studies.14–16 The 
MSTS93 score of the patient in our study was 28 compared 
with 15.3±6.1 in Aljassir et al.16 
Conclusion
Metastasis of melanoma to the pelvis is indeed rare and has a 
poor prognosis. The goal of treatment is usually local control 
and prevention of distant metastases while preserving as much 
function and quality of life as possible. First-line treatment 
Table 1 The follow-up outcomes
VAS Harris MSTS93* TESS† SF-36
GH PF RP BP VT RE MH Soc
Preoperation 8 39 None None 25 30 20 10 30 35 20 25
Six-month follow-up 3 76 26 80 70 60 50 70 55 80 50 50
Last follow-up 1 85 28 90 90 85 80 80 80 85 90 85
Notes: *MSTS93 maximum score =30. †TESS maximum score =100.
Abbreviations: VAS, visual analog scale; Harris, Harris hip score; MSTS93, Revised Musculoskeletal Tumor Society Rating Scale; TESS, Toronto Extremity Salvage Score; 
SF-36, Medical Outcomes Study 36-Item Short-Form Health Survey; GH, general health; PF, physical function; RP, role physical; BP, bodily pain; VT, vitality; RE, role emotional; 
MH, mental health; Soc, social function.OncoTargets and Therapy
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of a single or local metastatic malignant melanoma should 
be surgical excision and reconstruction.
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